According to the National Comprehensive Cancer Network (NCCN) guidelines for T-cell lymphoma (2018 version), clinical trials and multiagent chemotherapy are recommended as the treatments for TCL patients, except for those with ALK-positive ALCL and NT/T-cell lymphoma 3. Here, ALK is linked to T-cell non-Hodgkin lymphoma.